US Stock Insider Trading | Silvergate Disclosed 1 Insider Trading Transaction on February 26

K-LinePoet · 2026-03-22T17:03:57+00:00

On February 26, 2026, Insulet Corporation disclosed that director Michael R. Minogue purchased 2030 shares on February 25 at an execution price of $246.23, with a total transaction value of approximately $498,000. Recent insider transactions also include buying and selling activities by other directors and executives, reflecting active trading among company management. The company focuses on developing insulin delivery systems for diabetes patients.

K-LinePoet

2026-03-22 17:03:57

Abstract generation in progress

On February 26, 2026, PODD disclosed a company insider transaction. Director MINOGUE MICHAEL R purchased 2,030 shares on February 25, 2026.

[Recent Insider Transactions]

Disclosure Date	Position	Name	Transaction Date	Buy/Sell	Quantity	Price per Share/USD	Total Amount/USD
February 26, 2026	Director	MINOGUE MICHAEL R	February 25, 2026	Buy	2,030	246.23	$499,800
February 23, 2026	Director	McEvoy Ashley	February 20, 2026	Buy	4,300	239.35	$1,029,200
February 17, 2026	Executive	Benjamin Eric	February 12, 2026	Sell	2,887	240.82	$695,200
February 17, 2026	Executive	Kapples John W.	February 12, 2026	Sell	1,929	240.82	$464,500
February 17, 2026	Executive	Singh Prem	February 12, 2026	Sell	861	240.82	$207,300
February 17, 2026	Executive	Cousin Laetitia	February 12, 2026	Sell	564	240.82	$135,800
February 17, 2026	Executive	Budden Lauren	February 12, 2026	Sell	622	240.82	$149,800
January 6, 2026	Executive	Cousin Laetitia	January 2, 2026	Sell	140	282.92	$39,600
January 6, 2026	Director	Huffines Robert Luther	December 31, 2025	Buy	50	284.24	$14,200
December 16, 2025	Director	Frederick Wayne A.I.	December 15, 2025	Sell	1,851	293.09	$542,500

[Company Profile]

Insulet Corporation, founded in 2000 in Delaware, primarily develops, manufactures, and sells its proprietary insulin delivery systems for insulin-dependent diabetics. The Omnipod platform includes: Omnipod 5 Automated Insulin Delivery System, Omnipod DASH Insulin Management System, Omnipod Insulin Management System, and the latest innovation, Omnipod G™. In 2023, it received approval from the U.S. Food and Drug Administration. The company also produces Pods for Amgen, used in the Neulasta Onpro kit, a delivery system for Neulasta that helps reduce infection risk after intensive chemotherapy.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.